About 15,224 results
FDA approves Cablivi® (caplacizumab-yhdp), the first Nanobody®-based medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP)

Feb 5th, 2019 - The U.S. Food and Drug Administration (FDA) has approved Cablivi® (caplacizumab-yhdp) in combination with plasma exchange and immunosuppression for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) in adults. Cablivi is the first FDA approved therapy specifically indicated for the treatment of aTTP.

Use of Active Surveillance or Watchful Waiting for Low-Risk Prostate Cancer and Management Trends Across Risk Groups in the United States, 2010-2015
Mahal, B. et. al.

Feb 10th, 2019 - Historically, most patients with low-risk prostate cancer (clinical category T1c-T2a, prostate-specific antigen level <10 ng/mL, and Gleason 6 disease) were treated with radical prostatectomy, while radiotherapy-based treatment was the favored approach for high-risk localized prostate cancer. However, conservative management of low-risk prostate cancer with active surveillance or watchful waiti...

Rate of life-threatening childbirth complications increasing sharply across U.S. racial, ethnic groups

May 2nd, 2019 - Racial and ethnic disparities in severe maternal morbidity — life-threatening maternal complications associated with childbirth — have persisted and increased at high rates among U.S. women, according to an analysis of nearly 20 years of California hospital records funded by the National Institutes of Health. Known risk factors for these complications — such as blood pressure disorders, asthma ...

Golombok Rust Inventory of Sexual Satisfaction (GRISS)

Apr 16th, 2019 - The GRISS is a 28-item questionnaire for the assessment of sexual dysfunction in heterosexual couples. The GRISS is used by relationship counsellors and clinics to identify and monitor sexual problems. It has also been used in clinical trials of new treatment approaches and pharmacological products designed for the treatment of sexual dysfunction.

JAMA Cardiology Clinical Guidelines Synopsis - American Heart Association/American College of Cardiology/Multisociety Guideline on the Management of Blood Cholesterol–Secondary Prevention

Apr 16th, 2019 - Atherosclerotic cardiovascular disease (ASCVD) is the most common cause of death in the United States.1 Most deaths from ASCVD occur in patients with preexisting ASCVD. Secondary prevention trials in patients with established ASCVD demonstrate that low-density lipoprotein cholesterol (LDL-C)–lowering therapy with statins reduces recurrent cardiovascular events. Recently, new nonstatin drugs, no...

Gluten Intolerance Definition

Apr 16th, 2019 - Celiac Disease, Non-Celiac Gluten Sensitivity, and Food Allergy: How are they different?

Botulism | Genetic and Rare Diseases Information Center (GARD)

Apr 15th, 2019 - A collection of disease information resources and questions answered by our Genetic and Rare Diseases Information Specialists for Botulism

FDA grants fast track, orphan drug designations to APR-246 for myelodysplastic syndrome

Apr 15th, 2019 - The FDA granted fast track designation to APR-246 for the treatment of patients with myelodysplastic syndrome who have TP53 mutations. The agency also granted orphan drug designation to APR-246 (Aprea Therapeutics) for treatment of myelodysplastic syndrome.

NCCN Flash Updates: NCCN Guidelines® and NCCN Compendium® for Acute Lymphoblastic Leukemia

Apr 14th, 2019 - NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Acute Lymphoblastic Leukemia. These NCCN Guidelines® are currently available as Version 1.2019

Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer: ASCO Clinical Practice Guideline

Apr 14th, 2019 - To develop recommendations for duration of adjuvant chemotherapy with a fluoropyrimidine and oxaliplatin for patients with completely resected stage III colon cancer based on the results of trials of 3 months compared with 6 months of treatment.

NCCN Flash Updates: NCCN Guidelines® and NCCN Compendium® for Hodgkin Lymphoma and Pancreatic Adenocarcinoma

Apr 14th, 2019 - NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and the Drugs & Biologics Compendium (NCCN Compendium®) for Hodgkin Lymphoma. These NCCN Guidelines® are currently available as Version 1.2019.

Cardio-Oncology Rehabilitation to Manage Cardiovascular Outcomes in Cancer Patients and Survivors

Apr 14th, 2019 - Cardiovascular disease is a competing cause of death in patients with cancer with early-stage disease. This elevated cardiovascular disease risk is thought to derive from both the direct effects of cancer therapies and the accumulation of risk factors such as hypertension, weight gain, cigarette smoking, and loss of cardiorespiratory fitness. Effective and viable strategies are needed to ...

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

Apr 13th, 2019 - Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes.

Gelesis Granted FDA Clearance to Market PLENITY™ — a New Prescription Aid in Weight Management

Apr 13th, 2019 - Gelesis, a biotechnology company developing first-in-class hydrogel therapeutics to treat obesity and other chronic diseases related to the gastrointestinal (GI) tract, today announced that the United States Food and Drug Administration (FDA) has cleared the Company’s lead product candidate, PLENITY™ (Gelesis100), as an aid in weight management in adults with a Body Mass Index (BMI) of 25–40 k...

FDA expands pembrolizumab indication for first-line treatment of NSCLC (TPS ≥1%)

Apr 10th, 2019 - On April 11, 2019, the Food and Drug Administration approved pembrolizumab (KEYTRUDA, Merck Inc.) for the first-line treatment of patients with stage III non-small cell lung cancer (NSCLC) who are not candidates for surgical resection or definitive chemoradiation or metastatic NSCLC. Patients’ tumors must have no EGFR or ALK genomic aberrations and express PD-L1 (Tumor Proportion Score [TPS] ≥1...

Musical hallucinations and their relation with epilepsy
Journal of Neurology;

Apr 9th, 2019 - Musical hallucinations are poorly understood phenomena. Their relation with epilepsy was first described over a century ago, but never systematically explored. We, therefore, reviewed the literature, and assessed all descriptions of musical hallucinations attributed to epileptic activity. Our search yielded 191 articles, which together describe 983 unique patients, with 24 detailed descriptions...

Lipid levels and the risk of hemorrhagic stroke among women
Rist, P. et. al.

Apr 9th, 2019 - Objective To examine the association between lipid levels and hemorrhagic stroke risk among women. Methods We performed a prospective cohort study among 27,937 women enrolled in the Women's Health Study with measured total cholesterol, low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C), as well as triglycerides. Strokes were confirmed by medical rec...

Hepatitis C Questions and Answers for Health Professionals

Apr 8th, 2019 - What are the case definitions for reportable hepatitis C virus (HCV) infections? The specific viral cause of illness cannot be determined based solely on signs, symptoms, history, or current risk factors, but must be verified by specific serologic testing

Screening for Breast Cancer in Average-Risk Women: A Guidance Statement From the American College of Physicians

Apr 8th, 2019 - Description: The purpose of this guidance statement is to provide advice to clinicians on breast cancer screening in average-risk women based on a review of existing guidelines and the evidence they include. Methods: This guidance statement is derived from an appraisal of selected guidelines from around the world that address breast cancer screening, as well as their included evidence. All...

Association Among Dietary Supplement Use, Nutrient Intake, and Mortality Among U.S. Adults
Chen, F. et. al.

Apr 8th, 2019 - Background: The health benefits and risks of dietary supplement use are controversial. Objective: To evaluate the association among dietary supplement use, levels of nutrient intake from foods and supplements, and mortality among U.S. adults. Design: Prospective cohort study. Setting: NHANES (National Health and Nutrition Examination Survey) data from 1999 to 2010, linked to Nation...